ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance [Yahoo! Finance]
ADMA Biologics Inc (ADMA)
Last adma biologics inc earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.admabiologics.com
Company Research
Source: Yahoo! Finance
ADMA Biologics, Inc. (NASDAQ:ADMA) markets BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency, and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics. In earnings for the third quarter of 2025, the firm provided updated guidance, noting that for 2025, total revenue was now expected to be $510 million, up from prior guidance of more than $500 million. The 2025 adjusted net income was also modestly adjusted to $158 million due to a higher effective tax rate. ADMA Biologics, Inc. (NASDAQ:ADMA) is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. While we acknowledge the potential of ADM
Show less
Read more
Impact Snapshot
Event Time:
ADMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADMA alerts
High impacting ADMA Biologics Inc news events
Weekly update
A roundup of the hottest topics
ADMA
News
- Should You Be Adding ADMA Biologics (NASDAQ:ADMA) To Your Watchlist Today? [Yahoo! Finance]Yahoo! Finance
- ADMA Biologics (NASDAQ:ADMA) had its "hold (c)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- 3 High Growth Tech Stocks To Watch In The US Market [Yahoo! Finance]Yahoo! Finance
- The Play On ADMA Biologics: A Discounted Stock With Good Prospects [Seeking Alpha]Seeking Alpha
- High Growth Tech Stocks In The US Market With Potential [Yahoo! Finance]Yahoo! Finance
ADMA
Earnings
- 11/5/25 - Miss
ADMA
Sec Filings
- 12/16/25 - Form 4
- 11/21/25 - Form 4
- 11/5/25 - Form 10-Q
- ADMA's page on the SEC website